InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the stock.

Separately, Piper Sandler restated an “overweight” rating and issued a $4.50 price target on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Price Performance

NSPR stock opened at $2.59 on Tuesday. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.85. The firm has a market cap of $64.44 million, a PE ratio of -3.40 and a beta of 0.90. The firm has a 50 day simple moving average of $2.82 and a 200 day simple moving average of $2.52.

InspireMD (NYSE:NSPR) last released its earnings results on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. The business had revenue of $1.74 million for the quarter, compared to analyst estimates of $1.74 million. During the same period in the prior year, the company earned ($0.24) earnings per share. As a group, sell-side analysts expect that InspireMD will post -0.82 earnings per share for the current year.

Institutional Investors Weigh In On InspireMD

An institutional investor recently raised its position in InspireMD stock. Rosalind Advisors Inc. lifted its position in InspireMD, Inc. (NYSE:NSPR) by 266.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,513,641 shares of the company’s stock after acquiring an additional 1,827,579 shares during the quarter. InspireMD makes up about 4.6% of Rosalind Advisors Inc.’s holdings, making the stock its 8th biggest holding. Rosalind Advisors Inc. owned 10.08% of InspireMD worth $6,272,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.